Total Payments
$19,896
2024 Payments
$7,143
Companies
7
Transactions
21
Medicare Patients
324,267
Medicare Billing
$14.7M
Payment Breakdown by Category
Consulting$15,754 (79.2%)
Other$2,500 (12.6%)
Travel$950.00 (4.8%)
Food & Beverage$692.27 (3.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $15,754 | 6 | 79.2% |
| Honoraria | $2,500 | 1 | 12.6% |
| Travel and Lodging | $950.00 | 1 | 4.8% |
| Food and Beverage | $692.27 | 13 | 3.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Seqirus USA Inc | $7,957 | 6 | $0 (2024) |
| Janssen Research & Development, LLC | $7,920 | 3 | $0 (2020) |
| Valneva Usa, Inc. | $3,778 | 3 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $104.89 | 5 | $0 (2022) |
| Bavarian Nordic A/S | $71.77 | 2 | $0 (2024) |
| Merck Sharp & Dohme LLC | $34.37 | 1 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $29.46 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,143 | 5 | Seqirus USA Inc ($7,094) |
| 2023 | $4,728 | 8 | Valneva Usa, Inc. ($3,778) |
| 2022 | $68.31 | 3 | Janssen Pharmaceuticals, Inc ($68.31) |
| 2021 | $36.58 | 2 | Janssen Pharmaceuticals, Inc ($36.58) |
| 2020 | $7,920 | 3 | Janssen Research & Development, LLC ($7,920) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Seqirus USA Inc | — | Consulting Fee | Cash or cash equivalent | $1,770.00 | General |
| 12/05/2024 | Bavarian Nordic A/S | — | Food and Beverage | In-kind items and services | $49.28 | General |
| 12/04/2024 | Seqirus USA Inc | — | Food and Beverage | In-kind items and services | $54.43 | General |
| 08/06/2024 | Seqirus USA Inc | — | Consulting Fee | Cash or cash equivalent | $5,245.70 | General |
| 04/29/2024 | Seqirus USA Inc | — | Food and Beverage | In-kind items and services | $23.73 | General |
| 12/19/2023 | Seqirus USA Inc | — | Food and Beverage | In-kind items and services | $45.19 | General |
| 12/04/2023 | Valneva Usa, Inc. | — | Honoraria | Cash or cash equivalent | $2,500.00 | General |
| 12/01/2023 | Valneva Usa, Inc. | — | Travel and Lodging | Cash or cash equivalent | $950.00 | General |
| 12/01/2023 | Valneva Usa, Inc. | — | Food and Beverage | Cash or cash equivalent | $328.43 | General |
| 05/22/2023 | Bavarian Nordic A/S | — | Food and Beverage | In-kind items and services | $22.49 | General |
| 05/04/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $29.46 | General |
| 05/03/2023 | Seqirus USA Inc | — | Consulting Fee | Cash or cash equivalent | $818.00 | General |
| 02/19/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $34.37 | General |
| 03/08/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $30.75 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 02/16/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $24.99 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 02/08/2022 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $12.57 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/17/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 05/21/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $21.42 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 12/17/2020 | Janssen Research & Development, LLC | SIRTURO (Drug) | Consulting Fee | Cash or cash equivalent | $2,640.00 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 12/17/2020 | Janssen Research & Development, LLC | SIRTURO (Drug) | Consulting Fee | Cash or cash equivalent | $2,640.00 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 12/17/2020 | Janssen Research & Development, LLC | SIRTURO (Drug) | Consulting Fee | Cash or cash equivalent | $2,640.00 | General |
| Category: Infectious Diseases & Vaccines | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 582 | 582 | $33,696 | $23,569 |
| 2022 | 17 | 17,982 | 18,141 | $1.1M | $780,443 |
| 2021 | 13 | 305,703 | 305,862 | $18.6M | $13.9M |
Total Patients
324,267
Total Services
324,585
Medicare Billing
$14.7M
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 0124A | Adm sarscv2 bvl 30mcg/.3ml a | Office | 2023 | 218 | 218 | $13,298 | $10,060 | 75.6% |
| 0134A | Adm sarscv2 bvl 50mcg/.5ml a | Office | 2023 | 136 | 136 | $8,296 | $6,216 | 74.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 114 | 114 | $6,042 | $3,845 | 63.6% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2023 | 92 | 92 | $3,772 | $1,940 | 51.4% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 22 | 22 | $2,288 | $1,508 | 65.9% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 2,973 | 2,977 | $309,608 | $203,973 | 65.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 5,056 | 5,096 | $270,088 | $171,862 | 63.6% |
| 0124A | Fee covid-19 vac 13 res | Office | 2022 | 2,372 | 2,372 | $144,692 | $106,909 | 73.9% |
| 0064A | Adm sarscov2 50mcg/0.25mlbst | Office | 2022 | 1,914 | 1,973 | $120,353 | $89,261 | 74.2% |
| 0054A | Adm sarscv2 30mcg trs-sucr b | Office | 2022 | 1,896 | 1,928 | $117,608 | $87,951 | 74.8% |
| 0134A | Fee covid-19 vac 14 res | Office | 2022 | 983 | 983 | $59,963 | $43,756 | 73.0% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2022 | 1,942 | 1,966 | $80,606 | $41,400 | 51.4% |
| 0004A | Adm sarscov2 30mcg/0.3ml bst | Office | 2022 | 370 | 370 | $22,570 | $16,759 | 74.3% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 191 | 191 | $5,730 | $5,635 | 98.3% |
| 0052A | Adm sarscv2 30mcg trs-sucr 2 | Office | 2022 | 69 | 69 | $4,209 | $3,158 | 75.0% |
| 0051A | Adm sarscv2 30mcg trs-sucr 1 | Office | 2022 | 63 | 63 | $3,843 | $2,882 | 75.0% |
| 0031A | Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, dna, spike protein, adenovirus type 26 (ad26) vector, preservative free, 5x1010 viral particles/0.5ml dosage, single dose | Office | 2022 | 36 | 36 | $2,196 | $1,650 | 75.1% |
| 0013A | Adm sarscov2 100mcg/0.5ml3rd | Office | 2022 | 32 | 32 | $1,952 | $1,431 | 73.3% |
| 0001A | Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 30 mcg/0.3ml dosage, diluent reconstituted; first dose | Office | 2022 | 25 | 25 | $1,525 | $1,128 | 74.0% |
| 0012A | Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 100 mcg/0.5ml dosage; second dose | Office | 2022 | 24 | 24 | $1,464 | $1,082 | 73.9% |
| 0011A | Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 100 mcg/0.5ml dosage; first dose | Office | 2022 | 19 | 19 | $1,159 | $844.97 | 72.9% |
| 0002A | Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (covid-19) vaccine, mrna-lnp, spike protein, preservative free, 30 mcg/0.3ml dosage, diluent reconstituted; second dose | Office | 2022 | 17 | 17 | $1,037 | $762.37 | 73.5% |
| 0064A | Fee covid-19 vac 7 res | Office | 2021 | 107,217 | 107,227 | $6.5M | $4.9M | 74.8% |
| 0004A | Fee covid-19 vac 1 res | Office | 2021 | 94,579 | 94,600 | $5.8M | $4.4M | 75.7% |
| 0003A | Fee covid-19 vac 1 booster | Office | 2021 | 54,026 | 54,031 | $3.3M | $2.5M | 75.5% |
About Darvin Smith
Darvin Smith is a Infectious Disease healthcare provider based in Redwood City, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568548535.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Darvin Smith has received a total of $19,896 in payments from pharmaceutical and medical device companies, with $7,143 received in 2024. These payments were reported across 21 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($15,754).
As a Medicare-enrolled provider, Smith has provided services to 324,267 Medicare beneficiaries, totaling 324,585 services with total Medicare billing of $14.7M. Data is available for 3 years (2021–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Redwood City, CA
- Active Since 10/31/2006
- Last Updated 02/11/2022
- Taxonomy Code 207RI0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1568548535
Products in Payments
- SIRTURO (Drug) $7,920
- XARELTO (Drug) $104.89
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.